Top

Published in:

Open Access 20-09-2022 | Systemic Mastocytosis | Letter to the Editor

Towards personalized medicine with iPS cell technology: a case report of advanced systemic mastocytosis with associated eosinophilia

Authors: Salim Atakhanov, Deborah Christen, Benjamin Rolles, Herdit M. Schüler, Jens Panse, Nicolas Chatain, Steffen Koschmieder, Tim H. Brümmendorf, Marcelo A. S. Toledo, Martin Zenke

Published in: Annals of Hematology | Issue 11/2022

Excerpt

Dear Editor, …

Kluin-Nelemans HC, Reiter A, Illerhaus A et al (2020) Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. Leukemia 34:1090–1101. https://doi.org/10.1038/S41375-019-0632-4CrossRefPubMed

Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405. https://doi.org/10.1182/BLOOD-2016-03-643544CrossRefPubMed

Kirschner M, Maurer A, Wlodarski MW et al (2018) Recurrent somatic mutations are rare in patients with cryptic dyskeratosis congenita. Leukemia 32:1762–1767. https://doi.org/10.1038/S41375-018-0125-XCrossRefPubMed

Gotlib J, Pardanani A, Akin C et al (2013) International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121:2393–2401. https://doi.org/10.1182/BLOOD-2012-09-458521CrossRefPubMedPubMedCentral

Liu Y, Wang Y, Gao Y et al (2015) Efficient generation of megakaryocytes from human induced pluripotent stem cells using food and drug administration-approved pharmacological reagents. Stem Cells Transl Med 4:309–319. https://doi.org/10.5966/sctm.2014-0183CrossRefPubMedPubMedCentral

Satoh T, Toledo MAS, Boehnke J et al (2021) Human DC3 antigen presenting dendritic cells from induced pluripotent stem cells. Front Cell Dev Biol 9:667304. https://doi.org/10.3389/fcell.2021.667304

Toledo MAS, Gatz M, Sontag S et al (2021) Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. Blood 137:2070–2084. https://doi.org/10.1182/blood.2019004509CrossRefPubMed

Ma Z, Toledo MAS, Wanek P et al (2022) Cell cluster sorting in automated differentiation of patient-specific induced pluripotent stem cells towards blood cells. Front Bioeng Biotechnol 10:755983. https://doi.org/10.3389/fbioe.2022.755983CrossRefPubMedPubMedCentral

Elanzew A, Nießing B, Langendoerfer D et al (2020) The StemCellFactory: a modular system integration for automated generation and expansion of human induced pluripotent stem cells. Front Bioeng Biotechnol 8:1155. https://doi.org/10.3389/fbioe.2020.580352CrossRef

Title: Towards personalized medicine with iPS cell technology: a case report of advanced systemic mastocytosis with associated eosinophilia
Authors: Salim Atakhanov
Deborah Christen
Benjamin Rolles
Herdit M. Schüler
Jens Panse
Nicolas Chatain
Steffen Koschmieder
Tim H. Brümmendorf
Marcelo A. S. Toledo
Martin Zenke
Publication date: 20-09-2022
Publisher: Springer Berlin Heidelberg
Keywords: Systemic Mastocytosis
Eosinophilia
Imatinib
Published in: Annals of Hematology / Issue 11/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-022-04975-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2022

Catheter management across patients with hematologic malignancies and catheter-related blood stream infections: a systematic review

Clinical usefulness of a novel classification of T cell distribution patterns in the tumor microenvironment of follicular lymphoma to detect transformation

Cardiopulmonary testing in adult patients with β-thalassemia major in comparison to healthy subjects

CALR loss-of-heterozygosity as a potential driver for extramedullary AML

A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia

A case of JAK2 V617F positive essential thrombocythemia successfully controlled by imatinib mesylate

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials